Clinical Trials Arena on MSN
Edgewise reports positive top-line results from Phase II CIRRUS-HCM trial
In Part D, designed to support Phase III, dosing was determined by LVOT-G for oHCM and NT-proBNP for nHCM.
Because life expectancy and the prevalence of risk factors such as hypertension, obesity and diabetes are rising globally, heart failure (HF) is growing into a major health problem. Impairment of left ...
Whether left ventricular (LV) systolic properties are reduced in diastolic heart failure (DHF) remains controversial, because patients with DHF maintain a normal stroke volume and ejection fraction ...
Left ventricular hypertrophy (LVH) is prognostically relevant, associated with major cardiovascular risk factors and with atherosclerosis. However, whether LVH is independently associated with ...
It is a common perception that approximately 50% of heart failure (HF) patients present with a normal or near-normal left ventricular (LV) ejection fraction ("HF with preserved systolic function"), ...
Background The Forrester classification remains a cornerstone for assessing haemodynamic status in heart failure, yet its ...
Background: Prolonged steady state exercise can lead to a decrease in left ventricular (LV) function as well as promote the release of cardiac troponin T (cTnT). There is limited information on the ...
Obstructive sleep apnea subjects the failing heart to adverse hemodynamic and adrenergic loads and may thereby contribute to the progression of heart failure. We hypothesized that treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results